Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CMND

Clearmind Medicine Inc

May 26 • 03:23PM ET

2.55

+0.29 12.83 %

Healthcare • Biotechnology • Canada • Nano • NASD

Today, 8:30 AMClearmind Medicine gets Johns Hopkins IRB approval to advance CMND-100 Phase I/II alcohol use disorder trial

Peers: DRUG GHRS CMPS ATAI NRXP

| Held by: PSIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-24.14	Insider Own	0.66%	Shs Outstand	1.50M	Perf Week	-32.91%
Market Cap	2.60M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.01M	Perf Month	-68.59%
Enterprise Value	-7.74M	PEG	-	EPS next Q	-	Inst Own	0.22%	Short Float	4.33%	Perf Quarter	-78.02%
Income	-6.64M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.07	Perf Half Y	-96.79%
Sales	0.00M	P/B	0.46	EPS next Y	-	ROA	-74.91%	Short Interest	0.04M	Perf YTD	-85.91%
Book/sh	5.49	P/C	0.25	EPS next 5Y	-	ROE	-119.72%	52W High	524.00 -99.51%	Perf Year	-99.34%
Cash/sh	10.17	P/FCF	-	EPS past 3/5Y	83.49% 39.75%	ROIC	-80.60%	52W Low	2.10 21.43%	Perf 3Y	-99.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	27.21% 12.23%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	54.05%	Oper. Margin	-	ATR (14)	0.96	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.79	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	29.93	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	3.79	EPS Q/Q	65.27%	SMA20	-48.93%	Beta	-1.25	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-65.72%	Rel Volume	0.59	Prev Close	2.26
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-98.25%	Avg Volume	586.78K	Price	2.55
IPO	Aug 16, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	313,592	Change	12.83%

Today 08:25AM	Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts (GlobeNewswire) +12.83%
May-19-26 06:00AM	Clearmind Medicine Announces 1-for-10 Reverse Share Split (GlobeNewswire) -37.83%
May-18-26 11:17AM	Tirzepatide Combination Study Expands Clearminds Obesity Therapy Strategy (CMND) (InvestorsHub) -26.90%
10:30AM	BC-Most Active Stocks (Associated Press)
08:42AM	Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications (GlobeNewswire)
08:35AM	Loading…
May-15-26 08:35AM	Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. (GlobeNewswire)
May-12-26 08:41AM	Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder (GlobeNewswire)
May-11-26 07:55AM	Clearmind Medicine Announces "Inside MEAI" Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial (GlobeNewswire) -5.56%
May-05-26 08:50AM	Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD (GlobeNewswire) -9.56%
Apr-27-26 09:16AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -10.09%
07:41AM	Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation (GlobeNewswire)
Apr-20-26 04:03PM	Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care (GlobeNewswire) +58.42% -28.07%
10:30AM	BC-Most Active Stocks (Associated Press)
07:15AM	Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial (GlobeNewswire)
Apr-15-26 07:30AM	Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial (GlobeNewswire) -28.57%
10:30AM	Loading…
Apr-14-26 10:30AM	BC-Most Active Stocks (Associated Press) -36.36%
07:32AM	Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Mar-30-26 08:32AM	Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder (GlobeNewswire) +22.70%
Mar-27-26 07:32AM	Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders (GlobeNewswire) +10.41%
Mar-19-26 08:45AM	Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Mar-17-26 09:15AM	Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies (GlobeNewswire)
Mar-16-26 07:30AM	NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy (NewMediaWire) -5.13%
Mar-13-26 07:45AM	Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy (GlobeNewswire) -5.88%
Mar-11-26 09:07AM	Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results (GlobeNewswire) -6.28%
07:30AM	NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease (NewMediaWire)
Mar-10-26 08:59AM	Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks) +5.56%
Mar-04-26 07:30AM	Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval (GlobeNewswire)
Feb-19-26 01:05PM	Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss? (PR Newswire)
Feb-16-26 02:58PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
08:17AM	Loading…
Feb-09-26 08:17AM	Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial (GlobeNewswire) -8.15%
Feb-08-26 03:50PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-06-26 07:55AM	Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI (GlobeNewswire) -6.90%
Feb-03-26 08:00AM	Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments (GlobeNewswire) -5.83%
Jan-20-26 04:20PM	Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 (GlobeNewswire) +5.60%
Jan-14-26 08:55AM	Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 (GlobeNewswire)
Dec-31-25 09:10AM	Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Dec-24-25 09:15AM	Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth (GlobeNewswire) -5.76%
Dec-16-25 08:45AM	Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 (GlobeNewswire)
Dec-15-25 08:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -8.48%
Dec-12-25 08:32AM	Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment (GlobeNewswire)
06:32AM	Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement (GlobeNewswire)
Dec-10-25 04:15PM	Clearmind Medicine Announces 1-for-40 Reverse Share Split (GlobeNewswire) -6.08% -37.27%
Dec-05-25 05:00PM	Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Dec-02-25 07:57AM	Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -9.94%
Dec-01-25 08:56AM	Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial (GlobeNewswire) -6.92%
Nov-25-25 07:17AM	Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial (GlobeNewswire) -19.40%
Nov-24-25 08:51AM	Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review (GlobeNewswire) +8.41%
Nov-23-25 01:22PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-20-25 06:01AM	Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site (GlobeNewswire)
Nov-19-25 10:35AM	Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (NewMediaWire) -6.42%
Nov-18-25 08:56AM	Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -21.85%
Nov-17-25 07:55AM	Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (GlobeNewswire)
Nov-13-25 08:54AM	Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center (GlobeNewswire) +11.57%
Nov-12-25 06:25AM	Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment (GlobeNewswire) -32.32%
Nov-10-25 08:07AM	Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Nov-06-25 04:02PM	Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency (GlobeNewswire) -5.75% -7.70%
Nov-05-25 06:55AM	Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing (GlobeNewswire)
Nov-02-25 04:32PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-31-25 07:35AM	Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy (GlobeNewswire) -12.28%
Oct-30-25 07:55AM	Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -9.30%
Oct-28-25 08:08AM	Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar (GlobeNewswire)
Oct-27-25 09:22AM	Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement (GlobeNewswire)
Oct-21-25 07:25AM	Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Oct-20-25 07:41AM	Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders (GlobeNewswire) +11.71%
Sep-25-25 07:40AM	Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies (GlobeNewswire)
Sep-19-25 08:20AM	Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities (GlobeNewswire) +19.00%
Aug-07-25 07:32AM	SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar (GlobeNewswire) +6.23%
07:32AM	Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar (GlobeNewswire)
Aug-05-25 08:15AM	Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center (GlobeNewswire)
Jul-30-25 08:18AM	Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire)
08:12AM	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire)
Jul-23-25 08:55AM	Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder (GlobeNewswire)
Jul-20-25 07:00PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-15-25 08:05AM	Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled (GlobeNewswire)
Jul-09-25 06:15AM	Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck (GlobeNewswire) -6.42%
Jul-03-25 08:47AM	Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center (GlobeNewswire) +21.82%
Jun-30-25 09:16AM	Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Jun-28-25 09:10AM	Clearmind Medicine expands global clinical trial targeting AUD market (TipRanks)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
09:00AM	Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market (GlobeNewswire)
Jun-25-25 07:48AM	Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment (GlobeNewswire)
Jun-24-25 08:06AM	Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics (GlobeNewswire)
Jun-23-25 07:55AM	Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
Jun-12-25 09:25AM	Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics (GlobeNewswire)
Jun-05-25 07:32AM	Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment (GlobeNewswire)
May-20-25 09:00AM	Clearmind Medicine to Host Live Webinar "Gazing Through the Crystal Ball" Featuring Leading Psychedelic Experts (GlobeNewswire)
May-12-25 07:32AM	Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction (GlobeNewswire)
Apr-25-25 11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
07:59AM	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders (GlobeNewswire)
07:55AM	Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders (GlobeNewswire)
Apr-23-25 08:25AM	Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites (GlobeNewswire)
Apr-21-25 09:15AM	Clearmind Medicine to Host Live Webinar Gazing Through the Crystal Ball Featuring Leading Psychedelic Experts (GlobeNewswire) -6.25%
Apr-17-25 07:38AM	Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior (GlobeNewswire) +15.46%
Apr-16-25 08:40AM	Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism (GlobeNewswire) +5.43%
Apr-11-25 11:05AM	Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial (TipRanks)
Apr-10-25 08:25AM	Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder (GlobeNewswire)
Apr-08-25 06:55AM	Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders (GlobeNewswire)

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

Chief Executive OfficerDr. Adi Zuloff-Shani Ph.D.

B.CommMr. Alan Mark Rootenberg B.Com.

Vice President of Business DevelopmentProf. Mark Haden M.S.W.

Accounting ManagerMs. Mylene Touboul

Chief of Global ImpactMs. Mary-Elizabeth Gifford

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMND

Clearmind Medicine Inc

Upgrade your Finviz experience